IGHV4-34: A Potential Drug Target and Biomarker (G28395)

Target Name: IGHV4-34

NCBI ID: G28395

IGHV4-34

Other Name(s): IGHV434 | VH | immunoglobulin heavy variable 4-34 | Immunoglobulin heavy variable 4-34

IGHV4-34: A Potential Drug Target and Biomarker

IGHV4-34 (IGHV434) is a protein that is expressed in the human erythrocytes, which are the red blood cells that transport oxygen throughout the body. IGHV4-34 is a member of the interleukin-4 (IL4) family of cytokines, which are a group of proteins that play a critical role in the regulation of immune and inflammatory responses.

IGHV4-34 has been identified as a potential drug target and has been shown to have a number of potential therapeutic benefits. One of the key reasons for its potential as a drug target is its involvement in the regulation of inflammation. IGHV4-34 has been shown to play a role in the regulation of both acute and chronic inflammation, and has been shown to have anti-inflammatory effects.

In addition to its potential therapeutic benefits, IGHV4-34 has also been shown to be a valuable biomarker for a number of diseases. For example, IGHV4-34 has been shown to be elevated in the blood of individuals with a variety of inflammatory diseases, including rheumatoid arthritis, asthma, and multiple sclerosis. Additionally, IGHV4-34 has been shown to be decreased in the blood of individuals with cancer, which may suggest that it could be a useful biomarker for cancer detection and monitoring.

Despite its potential as a drug target and biomarker, IGHV4-34 is still a relatively little-known protein. There is currently limited research on the specific biology of IGHV4-34, and much of the research that has been done on it is focused on its potential therapeutic applications. This is likely to change in the coming years, as researchers continue to study its role in the regulation of inflammation and its potential as a drug target.

In conclusion, IGHV4-34 is a protein that has the potential to be a valuable drug target and biomarker. Its involvement in the regulation of inflammation and its potential therapeutic applications make it a promising candidate for further research. As research continues to uncover the biology of IGHV4-34, it is likely to become an increasingly important protein in the field of immunology and inflammation.

Protein Name: Immunoglobulin Heavy Variable 4-34

Functions: V region of the variable domain of immunoglobulin heavy chains that participates in the antigen recognition (PubMed:24600447). Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:22158414, PubMed:20176268). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:20176268, PubMed:17576170)

The "IGHV4-34 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGHV4-34 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets